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Background & Aims: L-carnitine supplementation is proposed to be associated with reduced 33 
liver enzymes levels; however, previous findings are equivocal. The current systematic review 34 
and meta-analysis of controlled clinical trials was performed to assess the effect of L-carnitine 35 
supplementation on liver enzymes [alanine aminotransferase (ALT), aspartate 36 
aminotransferase (AST), and gamma-glutamyl transpeptidase (GGTP)] levels.  37 
Methods: Online databases, including PubMed, Web of science, Scopus, and Google Scholar, 38 
as well as the reference lists of identified relevant studies were searched from database 39 
inception up to June 2019. The risk of bias in individual studies was assessed using Cochrane 40 
Collaboration's tool. Data were pooled using the random-effects model and expressed as mean 41 
differences (MDs) with 95% confidence intervals (CIs).  42 
Results: In total, nineteen trials (1206 participants) met the eligibility criteria. Intervention 43 
duration ranged from 2 to 48 weeks and L-carnitine supplementation dose ranged from 500 to 44 
4000 mg/day. L-carnitine supplementation significantly reduced serum ALT (MD = -10.97 45 
IU/L, 95% CI: -16.46, -5.48), AST (MD = -9.03 IU/L, 95% CI: -12.73, -5.33), and GGTP (MD 46 
= -7.88 IU/L, 95% CI: -12.11, -3.64) levels. The subgroup analysis showed that L-carnitine 47 
might be more effective in reducing liver enzymes with higher doses (≥ 2000 mg/day), longer 48 
treatment durations (> 12 weeks), and also among patients with liver diseases. 49 
Conclusion: L-carnitine supplementation significantly improves circulating ALT, AST and 50 
GGTP levels; therefore, it might positively affect liver function, especially among patients with 51 
liver diseases.  52 
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Aspartate aminotransferase (AST) and alanine aminotransferase (ALT), which are also known 56 
as serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase 57 
(SGPT), respectively, are found in the liver, heart cells, red blood cells, muscle tissue, and other 58 
organs, such as the pancreas and kidneys; however they are mainly produced in the liver (1, 2). 59 
These enzymes play a key role in transferring the α-amino group from alanine and aspartate, 60 
to the α-keto group of ketoglutaric acid to produce pyruvic acid and oxalacetic acid 61 
respectively, which are important in gluconeogenesis and amino acid metabolism (3-5). 62 
Although measurement of serum ALT and AST levels is primarily used for the diagnosis of 63 
hepatic disease, the elevation of aminotransferase levels is not specific to liver disease. AST, 64 
which appears in skeletal muscle, the brain, the heart and red blood cells, is less specific for 65 
liver damage (6, 7). The concentration of ALT is found to be lower than AST in all cells, except 66 
in hepatic cells; therefore, its elevation is particularly related to liver disease (8-10). Gamma-67 
glutamyl transpeptidase (GGTP) is another nonspecific marker of liver disease and also found 68 
in other organs; it is a plasma membrane enzyme that can counteract oxidative stress by 69 
increasing intracellular glutathione synthesis (11, 12). The consumption of even small amounts 70 
of alcohol increases the GGTP levels, and therefore, may be used as a biological marker for 71 
acute or chronic alcohol abuse (13, 14).  72 
Several epidemiological associations have been reported between these enzymes, which are 73 
regarded as markers of liver dysfunction and type 2 diabetes mellitus (15-17), cardiovascular 74 
disease (1, 18-20), and mortality from vascular and non-vascular diseases (21-23). With regard 75 
to many conditions which might increase liver enzymes, assessment and treatment should be 76 
focused on identifying and eliminating harmful agents, concurrent to applying the appropriate 77 
medical therapy and non-pharmacological treatments.  78 
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Carnitine (β-hydroxy-γ-N-trimethyl aminobutyric acid), regarded as vitamin BT, is the generic 79 
phrase for a number of compounds like L-carnitine, acetyl-L-carnitine, and propinyl-L-80 
carnitine (24, 25).  L-carnitine is the active form of carnitine, which is found in the body, food 81 
and most dietary supplements (26), and  is responsible for the transfer of fatty acids to 82 
mitochondria and, consequently, involved in energy production through β-oxidation of fatty 83 
acids (27, 28).  L-carnitine supplementation has been shown to be beneficial in the prevention 84 
or treatment of end-stage kidney disease (29), cardiovascular disease (30), dialysis-related 85 
hypertension (31), persistent depressive disorder (32), non-alcoholic fatty liver disease (33), 86 
and sarcopenia in patients with liver cirrhosis (34). Recently, it has been proposed that L-87 
carnitine supplementation might be effective in reducing serum liver ALT levels (35-38). 88 
Several clinical trials have evaluated the effect of L-carnitine supplementation on the levels of 89 
liver enzymes; however, the evidence remains inconclusive. Although a number of studies 90 
provide evidence that consuming L-carnitine might be effective in reducing these enzymes (35-91 
38), others demonstrate no significant effect on serum ALT and AST levels (39-44).  92 
To the best of our knowledge, no study has yet attempted to summarize the published evidence 93 
regarding the effect of L-carnitine supplementation on serum levels of enzymes mainly 94 
produced by the liver. Therefore, the present study aimed to perform a systematic review and 95 
meta-analysis of controlled clinical trials to assess the effect of L-carnitine supplementation on 96 
serum liver enzymes (ALT, AST, and GGTP) in adults.   97 
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MATERIALS AND METHOD  98 
The present systematic review and meta-analysis is reported based on preferred reporting items 99 
for systematic reviews and meta-analyses (PRISMA) guidelines and aimed to investigate the 100 
effect of L-carnitine supplementation on circulating ALT, AST, and GGTP levels in adults. 101 
The study protocol was registered and ethically approved by the research council of Shahid 102 
Sadoughi University of Medical Sciences (registration code: IR.SSU.SPH.REC.1398.016). 103 
 104 
Search strategy  105 
Relevant articles were identified by searching PubMed (www.pubmed.com), Scopus 106 
(http://www.scopus.com), ISI Web of Science (www.webofknowledge.com), and Google 107 
Scholar (www.scholar.google.com) from the earliest available online indexing year to June 108 
2019. No language restriction or other filters were applied when searching the literature. The 109 
following groups of medical subject headings (MeSH) and non-MeSH keywords were used: 110 
keywords group 1: “carnitine”, “levocarnitine”, “vitamin BT”, “bicarnesine”, 111 
“acetylcarnitine”, “hydroxyisovalerylcarnitine”, “palmitoylcarnitine”, “L-carnitine”,   112 
“propionyl-L-carnitine”, “L-carnitine L-tartrate”, “L-Carnitine-L-tartrate”, “L-carnitine 113 
Tartrate”; keywords group 2:  “intervention”, “trial”, “randomized”, “random”, “randomly”, 114 
“placebo”, “assignment”, “clinical trial”, “RCT”, “cross-over”, “parallel”, “steatosis”, 115 
“steatoses”, “non-alcoholic fatty liver disease”, “nonalcoholic fatty liver disease”, “NAFLD”, 116 
“nonalcoholic fatty liver”, “nonalcoholic steatohepatitis”, “nonalcoholic steatohepatitides”, 117 
“alanine transaminase”, “glutamic-alanine transaminase”, “glutamic alanine”, “alanine-2-118 
oxoglutarate aminotransferase”, “alanine 2 oxoglutarate aminotransferase”, “ALT”, “alanine 119 
aminotransferase”, “SGPT”, “glutamic-pyruvic transaminase”, “glutamic pyruvic 120 
transaminase”, “SGOT”, “glutamic-oxaloacetic transaminase”, “glutamic oxaloacetic 121 
transaminase”, “AST”, “aspartate aminotransferases”, “aspartate apoaminotransferase”, 122 
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“aspartate transaminase”, “glutamic-oxaloacetic transaminase”, “glutamic oxaloacetic 123 
transaminase”, “L-aspartate-2-oxoglutarate aminotransferase”, “L aspartate 2 oxoglutarate 124 
aminotransferase”, “glutamate-aspartate transaminase”, “glutamate aspartate transaminase”, 125 
“GGTP”, “gamma-glutamyl transpeptidase”, “ALP”, “alkaline phosphatase”; Keywords group 126 
3: “mouse”, “mice”, “rats”, “in vitro”, “pig”, “rabbit”, “rooster”, “cell”, “cow”. Group 1 127 
keywords were combined with group 2 by “AND” operator and the “NOT” Boolean was used 128 
to remove publications with keywords group 3 in their titles/abstracts. Moreover, the keywords 129 
related to anthropometric indices, glycemic and inflammatory markers, blood pressure, lipid 130 
profile, and oxidative stress were used to find relevant studies reporting liver enzymes as 131 
secondary outcomes. The details on search strategy for PubMed, Scopus, and ISI web of 132 
science are provided in the Supplementary Table 1. 133 
 134 
Eligibility criteria 135 
The population, intervention, comparison, outcome, and study types (PICOS) criteria used for 136 
the current study are shown in Table 1. The following inclusion criteria were considered for 137 
selecting the relevant investigations: 1) studies which were controlled clinical trial in design 138 
(randomized or non-randomized); 2) studies which assessed the effect of L-carnitine 139 
supplementation on circulating liver enzymes [e.g. ATL, AST, and other possible markers like 140 
gamma-glutamyl transpeptidase (GGTP), and alkaline phosphatase (ALP)] levels; 3) studies 141 
conducted in adults aged 18 years and more.  142 
Trials were excluded for the following reasons: 1) they were performed in children or 143 
adolescents aged younger than 18 years; 2) studies with ≤ 1 week (wk) of intervention duration; 144 
3) trials in which the difference between the intervention and control group was in other 145 
components in addition to L-carnitine supplementation; 4) studies in which L-carnitine was 146 
injected intravenously or intramuscularly; 5) studies which did not assess outcomes of interest; 147 
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6) studies reporting duplicate data. In the case of several publications with the same data set, 148 
publications with more complete data were selected. 149 
The preliminary screening of titles and abstracts of all identified articles, as well as further 150 
reviewing of the full-texts of the eligible papers, were independently done by two investigators 151 
(FP and NT), and any disagreement was resolved by consulting other authors (ASA, MM, and 152 
NRJ). In addition, the reference lists of relevant original and review articles were manually 153 
scanned to identify any other potentially eligible studies. 154 
 155 
Data extraction 156 
The data extracting process was done by 2 independent reviewers (FP and NT). This process 157 
was approved by other investigators (ASA, MM, and NRJ). The following information was 158 
recorded from eligible studies: the last name of the first author, the year of publication, the 159 
country in which the study was implemented, the design of the study, intervention duration 160 
(weeks), the mean/range of participants’ age, the number of participants, the participants' health 161 
status, the dosage of L-carnitine supplement (mg/day), the intervention carried out in the 162 
control group, and the outcome measures. To obtain the data that were not mentioned in the 163 
studies, we emailed the corresponding authors of the eligible publications. 164 
 165 
Risk of bias assessment in individual studies 166 
Two independent investigators (FP and NT) assessed the risk of bias in the included studies 167 
using the Cochrane risk of bias tool. Six domains were considered: (i) random sequence 168 
generation (selection bias); (ii) allocation concealment (selection bias); (iii) blinding of 169 
participants and personnel (performance bias); (iv) blinding of outcome assessment (detection 170 
bias); (v) incomplete outcome data (attrition bias); (vi) selective reporting (reporting bias). The 171 
included investigations were judged to be "low risk of bias", "high risk of bias", or "unclear 172 
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risk of bias" regarding each domain. A study was considered as a low risk of bias if it received 173 
a low risk of bias for all domains, unclear risk if it was unclear regarding the risk of bias for 174 
one or more domains and high risk of bias if it was a high risk of bias for one or more domains 175 
(45).  176 
 177 
Assessment of the overall quality of the meta-analysis 178 
The overall quality of the met-evidence provided by the current study was assessed using the 179 
NutriGrade scoring system, which uses a scoring system (with maximum of 10 points) to judge 180 
the quality of meta-analyses of clinical trials conducted in the field of nutrition. This tool 181 
considers the following domains: risk of bias/study quality/study limitations (3 points), 182 
precision (1 point), heterogeneity (1 point), directness (1 point), funding bias (1 point), 183 
publication bias (1 point), and study design (2 point) (46). NutriGrade suggests 4 categories for 184 
the overall quality of meta-evidence, including high (≥ 8 points), moderate (6-7.99 points), low 185 
(4-5.99 points) and very low (≤ 3.99 points). 186 
 187 
Statistical analysis 188 
The mean change values from baseline to follow-up and their standard deviations (SDs) for 189 
intervention and control groups/periods were extracted to calculate the mean difference and its 190 
corresponding standard error (SE), which was used as the effect size for meta-analysis. If the 191 
change values were not reported, we calculated the SD for mean change by calculating 192 
correlation coefficients (r = 0.76 for ALT and r = 0.65 for AST) from studies which already 193 
reported SDs for baseline, after intervention and change values for the intervention and the 194 
control groups (36, 38, 40, 42, 47). The correlation coefficients were used to calculate SD for 195 
change values for other studies (45). The overall mean differences (MDs) and their 196 
corresponding 95% confidence intervals (CIs) were calculated by using the random effects 197 
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model that takes the between-study heterogeneity into account (48). The Cochrane Q test and 198 
I-squared statistic (I2 is an estimate ranging from 0-100%, with lower values indicating less 199 
heterogeneity) were used to assess the heterogeneity between studies (49). The possible sources 200 
of heterogeneity were explored by using subgroup analysis based on the health status of 201 
participants (liver disease/without liver disease), type of control group (without 202 
treatment/placebo/drug), follow-up time (≤12 weeks / >12 weeks), and dosage of L-carnitine 203 
supplement (<2000 mg/d / ≥2000 mg/d). Sensitivity analysis was used to assess the robustness 204 
of the meta-analyses results by sequentially removing individual included studies. The 205 
presence of publication bias was assessed for each outcome through statistical asymmetry tests 206 
(Egger's regression asymmetry test and Begg’s adjusted rank correlation test), and also by 207 
visually inspecting Begg’s funnel plot. All statistical analyses were performed using STATA, 208 
version 11.2 (Stata Corp, College Station, TX) and a two-sided P-values < 0.05 were 209 





Study selection 213 
The literature search retrieved 6321 publications, of which 1355 papers were duplicates, and 214 
4920 papers were excluded after screening the titles and abstracts. After full-text assessment 215 
of 46 potentially relevant records, 27 studies were excluded because they did not report the 216 
outcomes of interest (n=14) (50-63); supplemented other components in addition to L-217 
carnitine, and the difference between the two groups/periods was not only in L-carnitine (n=3) 218 
(64-66); included duplicate data from the other studies (n=7) (67-73); administered L-carnitine 219 
intramuscularly (n=1) (74); the intervention period was lower than 2 weeks (n=1) (75); 220 
conducted in participants aged younger than 18 years (n=1) (76). Finally, 19 controlled clinical 221 
trials which studied a total of 1206 subjects were selected to be included in the present 222 
systematic review and meta-analysis (35-44, 47, 77-84). The detailed steps of the study 223 
selection process are shown in Figure 1. 224 
 225 
Study and participant characteristics 226 
Twelve studies were carried out in Asian countries (37, 40-44, 77-79, 82-84) and seven studies 227 
were done in European countries (35, 36, 38, 39, 47, 80, 81), published between 1996 and 228 
2016. All trials used a parallel design, except one study which used cross over design (80), and 229 
the intervention period in these studies ranged between 2 and 48 wks. L-carnitine was orally 230 
administered and the intervention dose ranged between 500 to 4000 mg/day. For the control 231 
groups, ten trials used placebo controls (35, 36, 39, 44, 79-84), six trials did not prescribe any 232 
treatment (37, 40-43, 77), and three trials used drugs such as interferon-α, ribavirin, and 233 
entecavir, in which participants in the intervention group also received these drugs in addition 234 
to L-carnitine (38, 47, 78). The majority of trials included either gender, with the age ranging 235 
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from 18 to 85 years. The sample size of included studies ranged from 30 to 131 participants. 236 
Nine trials were conducted among participants who had liver diseases (36-38, 43, 47, 77-79, 237 
81). Two trials were done in hemodialysis patients (40, 41), one study included participants 238 
with hypothyroidism (44), cystic acne patients (35) and thyroid patients (80). One study was 239 
conducted in obese women (42), three trials included healthy participants (39, 82, 83) and one 240 
study included patients with suspected acute myocardial infraction (84). The characteristics of 241 
the included studies are detailed in Table 2. 242 
 243 
Risk of bias assessment 244 
A summary of the risk of bias assessment of the included studies is presented in Table 3. 245 
Although the description for the random generation was well-addressed in six studies (36, 38, 246 
41, 44, 47, 78, 79, 82), others did not explain random sequence generation method, and one of 247 
the studies was not randomized (37). Two trials included information about allocation 248 
concealment (82, 85). Four studies were considered to be a low risk of bias regarding blinding 249 
of participants and personnel (36, 39, 79-85). In the majority of included trials, the blinding of 250 
outcome assessment was unclear. Incomplete outcome data were addressed in thirteen studies 251 
(36, 38-41, 44, 47, 78, 79, 81-84). All trials were categorized as low risk of bias for selective 252 
outcome reporting. Considering the six domains of the Cochrane collaborations’ risk of bias 253 
assessment tool, fifteen trials were judged to have a moderate or unclear risk, and four trials 254 
had a high risk of bias. 255 
 256 
The effect of L-carnitine on serum alanine aminotransferase (ALT) concentrations 257 
Seventeen trials, including 1091 participants, provided data on the effect of L-carnitine 258 
supplementation on serum ALT levels (35-43, 47, 77-81, 83, 85). The pooled effect size 259 
indicated that consuming L-carnitine significantly reduced ALT concentrations (MD = -10.97 260 
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IU/L, 95% CI: -16.46, -5.48, P < 0.001), with high between-study heterogeneity (Q statistic = 261 
606.33, Cochrane Q test, P < 0.001; I2 = 97.4). Although, heterogeneity was not reduced by 262 
several subgroup analyses, the results showed that serum ALT levels were reduced to a greater 263 
magnitude in patients with liver diseases (MD = -20.25 IU/L, 95% CI: -31.22, -9.28, P < 0.001; 264 
Figure 2A), compared with subjects without liver diseases (MD = -2.84 IU/L, 95% CI: -5.33, 265 
-0.34, P = 0.026). In another subgroup analysis, based on the type of control group, in studies 266 
which administered placebo or drug for the control group compared with studies that did not 267 
use any treatment for controls, a significant reduction in the levels of ALT was observed. There 268 
was also a significant reduction in serum ALT concentrations following L-carnitine 269 
supplementation in studies which used high doses of L-carnitine (≥ 2000 mg/day) for 270 
supplementation (MD = -14.08 IU/L, 95% CI: -22.72, -5.44, P = 0.001; Figure 3A). However, 271 
significant changes were not observed in lower intervention doses. Moreover, the reducing 272 
effect of L-carnitine on serum ALT levels was seen in both subgroups of duration; however, 273 
the effect was lower for studies with a duration of shorter than 12 weeks. Table 4 shows the 274 
meta-analysis results for subgroup as well as overall analyses. 275 
 276 
The effect of L-carnitine on serum aspartate aminotransferase (AST) concentrations 277 
The results of the overall analysis of eighteen studies with 1087 participants (35-43, 47, 77, 79-278 
85) indicated that circulating AST levels following L-carnitine supplementation was 279 
significantly decreased compared to control groups (MD = -9.03 IU/L, 95% CI: -12.73, -5.33, 280 
P < 0.001). The heterogeneity between studies was significant (Q statistic =313.44, Cochran’s 281 
Q test, P < 0.001; I2 = 94.6), and was not explained by several subgroup analyses. The results 282 
of the subgroup analysis based on health status of participants indicated a greater reduction in 283 
serum AST levels among patients with liver diseases as compared to patients without liver 284 
disease (MD = -17.39, 95% CI: -24.10, -10.76, P < 0.001 vs. MD = -4.32, 95% CI: -7.45, -285 
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1.18, P = 0.007; Figure 2B). Pooled analysis of studies, in which control subjects received 286 
placebo or drug, showed a significant reduction, while there was no considerable difference in 287 
serum AST levels in studies with non-treated controls. We also observed that L-carnitine 288 
supplementation in studies with intervention doses of ≥ 2000 mg/day significantly reduced 289 
circulating AST levels compared with control groups (MD = -13.53, 95% CI: -19.43, -7.63, P 290 
< 0.001; Figure 3B), however, there was no significant change when the analysis was done for 291 
studies with intervention doses of less than 2000 mg/day. Moreover, the reducing effect of L-292 
carnitine on serum AST levels was seen in both subgroups of duration; however, the effect was 293 
lower for studies with a duration of shorter than 12 weeks. Table 4 details the overall, as well 294 
as subgroup analyses, results. 295 
 296 
The effect of L-carnitine on other liver enzymes 297 
The pooled estimate of six trials (35-37, 43, 80, 83) evaluating the effect of L-carnitine 298 
supplementation on serum GGTP levels showed a significant reduction (MD = -7.88 IU/L, 299 
95% CI: -12.11, -3.64, P < 0.001), with no significant between-study heterogeneity (Q statistic 300 
= 7.39, Cochran’s Q test, P = 0.193; I2 = 32.4%). 301 
 302 
Sensitivity analysis and publication bias 303 
The sensitivity analysis revealed that the significant effect of L-carnitine supplementation on 304 
circulating ALT and AST levels did not change by removing any of the included trials. The 305 
summary effect of the L-carnitine on GGTP levels changed to a non-significant reduction after 306 
removing the Lim et al. study (37) (MD = -10.08 IU/L, 95% CI: -20.55, 0.38) and Georgala et 307 
al. study (35) (MD = -9.84 IU/L, 95% CI: -21.51, 1.83). We also performed a sensitivity 308 
analysis to assess whether results varied by the quality of studies. The results showed that, by 309 
excluding the trials that had high risk of bias in overall assessment (37, 38, 41, 78), the 310 
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significant reducing effect of L-carnitine supplementation on circulating ALT and AST levels 311 
was unaltered. 312 
No evidence of publication bias was found regarding the effect of L-carnitine consumption on 313 
ALT (Begg’s test, P = 0.077; Egger’s test, P = 0.097) and GGTP (Begg’s test, P =1.00; Egger’s 314 
test, P = 0.918) levels. However, visual examination of funnel plot, as well as Begg’s and 315 
Egger’s asymmetry tests (Begg’s test, P =0.034; Egger’s test, P = 0.009), suggested evidence 316 
of publication bias for the meta-analysis of serum AST levels. However, using the trim and fill 317 
analysis, which conservatively imputes estimates from hypothetical negative unpublished 318 
studies, we found the results remained unchanged. 319 
 320 
Quality of meta-evidence 321 
The total scores of quality of meta-evidence, which was assessed using the NutriGrade scoring 322 
system, were 6.6 for ALT and AST (indicating moderate confidence in the effect estimate, 323 
which shows future well designed clinical trials are still needed to confirm our results), and 4.4 324 
for GGTP (indicating low confidence in the effect estimate, which shows further research will 325 




In the present systematic review and meta-analysis, we assessed the efficacy of L-carnitine 328 
supplementation in reducing serum liver enzyme levels; by reviewing the available published 329 
controlled intervention trials, for the first time. The synthesis of the data confirmed the 330 
beneficial effect of L-carnitine intake on decreasing ALT, AST, and GGTP levels. The 331 
subgroup analysis showed that L-carnitine might be more effective in reducing liver enzymes 332 
when higher doses (≥ 2000 mg/day) are supplemented, when the treatment duration is more 333 
than 12 weeks and also when the supplementation is done in patients with liver diseases. 334 
The absorption of oral L-carnitine across the intestinal cells occurs through both active and 335 
passive means of transport. These pathways assure the high concentration of L-carnitine in 336 
tissues that are dependent on fatty acids oxidation as a fuel source (86, 87). Oral 337 
supplementation of L-carnitine (1-6 gr) has been reported to have a biological availability 338 
between 5-18% (86), and this limited bioavailability might be associated with metabolization 339 
of L-carnitine by gut microbiota prior to absorption (88, 89). This point may be a logical 340 
explanation for the efficacy of higher doses of L-carnitine in reducing ALT and AST levels 341 
(30). It has been stated that supplementation with L-carnitine is regarded as safe for doses up 342 
to 15 g/day in healthy men (42), although doses of 100-400 mg/kg/day is recommended in 343 
carnitine deficiency, and, importantly, the L-carnitine dose should be compatible with each 344 
patient by measurement of plasma L-carnitine levels. A few side effects, like diarrhea, 345 
intestinal problems and the production of trimethylamine, resulting in a fishy odor, have also 346 
been observed following high doses of L-carnitine supplementation, which can be effectively 347 
treated by reducing the dosage (90). 348 
In the current meta-analysis, we observed a significant reduction in circulating ALT and AST 349 
levels following supplementation with L-carnitine in patients with and without liver diseases, 350 
however, this reduction was higher in patients with liver diseases compared with other 351 
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participants. Indeed, it seems that L-carnitine supplementation elicits a greater beneficial effect 352 
for patients who have high levels of liver enzymes at baseline. Since the liver is a major organ 353 
responsible for detoxification and metabolization of various compounds that produce reactive 354 
oxygen species (ROS), liver diseases might lead to increased ROS production (91, 92). 355 
Consequently, oxidative stress induces impairments in mitochondrial β-oxidation  (93, 94). The 356 
disruption of β-oxidation is a major contributor in the pathogenesis of nonalcoholic fatty liver 357 
disease, which causes the accumulation of fatty acids within the hepatocytes and the 358 
progression of the disease (95-97). Therefore, the essential role of L-carnitine in the transfer of 359 
the long-chain fatty acids inside mitochondria for β-oxidation might be a reason for reducing 360 
ALT and AST levels, especially in patients with liver disease (31, 98, 99). Furthermore, it has 361 
been proposed that L-carnitine, due to antioxidant and antiradical properties, might be useful 362 
in preventing oxidative stress and the activity of enzymes involved in defense reactions against 363 
oxidative damage (100). On the other hand, carnitine deficiency is more likely to occur in liver 364 
diseases (47, 101), which impairs the mitochondrial β-oxidation of fatty acids, causing acute 365 
metabolic decompensation with elevated transaminases, hepatic encephalopathy, hypoketotic 366 
hypoglycemia, and cardiomyopathy (102). Accordingly, the correction of carnitine deficiency 367 
by oral supplementation of L-carnitine might be beneficial in these patients (101). 368 
There are a number of limitations in the present meta-analysis, although some of them are 369 
associated with inherent shortcomings of clinical trials such as heterogeneous methodological 370 
approaches regarding the characteristics of participants (for instance, changes in carnitine 371 
metabolism in uremia and its depletion is expected in hemodialysis patients), L-carnitine 372 
dosage (500-4000 mg/d), and type of control group (placebo, drug or without treatment). 373 
Moreover, the duration of L-carnitine supplementation varied from study-to-study, therefore 374 
further studies are needed to examine the time-dependent effect of L-carnitine supplementation 375 
in reducing ALT and AST levels. Also, a number of the included studies did not explain the 376 
17 
 
method used to assess the adherence to the treatment, for instance, pill counts or measurement 377 
of serum carnitine (37, 39, 42, 43, 77, 78). On the other hand, the bioavailability of L-carnitine 378 
was not assessed in the included studies, so the amount of available L-carnitine in the blood 379 
after ingestion is not clearly specified. It is also important to note that these findings should not 380 
be generalized to patients with primary or secondary carnitine deficiency (caused by genetic 381 
alterations in renal handling or muscle transport of L-carnitine and impaired renal tubular 382 
resorption from drug toxicity or hemodialysis, respectively). In contrast to these limitations, 383 
there are several strengths in our study. We conducted a comprehensive and systematic search 384 
to identify all published studies on this topic. We also performed several subgroup analyses to 385 
evaluate the potentially different effects of L-carnitine supplementation caused by the 386 
intervention dose and duration, the type of control group, and the health status of the 387 
participants. Moreover, the findings of the present meta-analysis were not sensitive to the 388 
results of any one of the included studies, which highloghts the robustness of the findings. 389 
The present systematic review and meta-analysis provides evidence for the beneficial effects 390 
of L-carnitine supplementation in reducing serum liver enzyme levels. Our findings also 391 
showed that L-carnitine can be more effective among patients with liver diseases and with 392 
intervention doses of more than 2000 mg/day. However, since the majority of the included 393 
studies were judged to be have an “unclear” risk of bias, the authors suggest that further high-394 
quality trials, with an adequate duration and sample size, are conducted to reliably confirm the 395 
efficacy and safety of L-carnitine supplementation in improving liver enzymes.  396 
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Adults aged >18 year 
Intervention L-carnitine supplement  
Comparison 
 
Placebo, without treatment or other drugs/supplements 
Outcome Enzymes mainly produced by liver [.alanine aminotransferase (ATL), 
aspartate aminotransferase (AST), and other possible markers like 
gamma-glutamyl transpeptidase (GGTP), alkaline phosphatase 
(ALP)] 
   
Study types 
 















Sex (F/M)*  


















Parallel 12 Three tablet twice per 
day, 330 mg L-carnitine 














Parallel 12 750 mg L-carnitine 
three times day 
Placebo ALT 
AST 
Type 2 diabetic 
patients with 
NAFLD* 







Parallel 12 1000 mg/d L-carnitine Without treatment ALT 
AST 
Obese women with a 
BMI* ≥ 30 kg/m2 






















Parallel 48 20 mg/kg/day L-
carnitine 
Without treatment ALT 
AST 
Hemodialysis patient 







Parallel 24 500 mg/d L-carnitine Without treatment ALT 
AST 
Patient with NAFLD 






Parallel 24 900 mg/d L-carnitine Without treatment ALT 
AST 
Hemodialysis patient 






Parallel 48 2472 mg/d L-carnitine 
+ 0.5 mg entecavir 
0.5 mg entecavir ALT Hepatitis B patients  
27 
 






Con: 40.2  























Parallel 48 2000 mg L-carnitine 
twice a day + 1.5 
µg/kg/wk peg 
interferon-α 2b + 
ribavirin 
1.5 µg/kg/wk peg 




Patients with chronic 
hepatitis C virus 







Parallel 24 2000 mg/d L-carnitine 
+ 1600-calorie diet 





















alcoholic fatty liver 
disease 







Parallel 2 2000 mg/d L-carnitine 2000 mg/d Placebo ALT 
AST 
Healthy volunteers 






Parallel 12 2000 mg Acetyl-L-




with minimal hepatic 
encephalopathy 







Parallel 24 2000 mg/d L-carnitine 
+ 3 million IU 
Interferon-α three times 
a week 
3 million IU 
Interferon-α three 
times a week 
ALT 
AST 
Patient with chronic 










Cross-over 8 4000 mg/d L-carnitine 
+ l-thyroxine 

















Patient with cystic 
acne on isotretinoin 
therapy 











*ALT, alanin aminotransferase; AST, aspartat aminotransferase; GGTP, gamma-glutamyl transpeptidase; Con, control; F, female; Int, intervention M, male; NR, not reported; 

























An et al., 2016 (85) Low Low Low Unclear Low Low Unclear 
Alavinejad et al., 2016 (79) Low Unclear Low Unclear Low Low Unclear 
Mosah et al., 2015 (42) Unclear Unclear Unclear Unclear Unclear Low Unclear 
Hassan et al., 2015 (43) Unclear Unclear Unclear Unclear Unclear Low Unclear 
Higuchi et al., 2014 (41) Low High High Unclear Low Low High 
Somi et al., 2014 (77)  Unclear Unclear Unclear Unclear Unclear Low Unclear 
Fukami et al., 2013 (40) Unclear Unclear Unclear Unclear Low Low Unclear 
Jun et al., 2013 (78) Low High High Unclear Low Low High 
Odo et al., 2013 (83) Unclear Unclear Low Unclear Low Low Unclear 
Mohtadinia et al., 2013 (82) Low Low Low Unclear Low Low Unclear 
Malagurnera et al., 2011 (38)  Low High High Unclear Low Low High 
Malaguarnera et al., 2010 (36) Low Unclear Low Low Low Low Unclear 
Lim et al., 2010 (37)  High High High Unclear Unclear Low High 
Delas et al., 2008 (39) Unclear Unclear Low Unclear Low Low Unclear 
Malaguarnera et al, 2008 (81) Unclear Unclear Low Unclear Low Low Unclear 
Malaguarnera et al., 2002 (47) Low Unclear Unclear Unclear Low Low Unclear 
Benvenga et al., 2001 (80) Unclear Unclear Low Unclear Unclear Low Unclear 
Georgala et al., 1999 (35) Unclear Unclear Unclear Unclear Unclear Low Unclear 





Table 4- The effect of L-carnitine supplementation on serum ALT and AST levels based on 
several subgroups as well as all studies, using a random-effects model. 






difference (95% CI) 




(%) 2I P between 
group 
ALT (IU/L)         
Health status         
Liver disease 9 676 -20.25 (-31.22, -9.28) <0.001 143.59 <0.001 94.4 <0.001 
Without liver disease 8 415 -2.84 (-5.33, -0.34) 0.026 50.71 <0.001 86.2 
Control type         
Without treatment 6 436 -8.85 (-17.74, 0.04) 0.051 260.51 <0.001 98.1 <0.001 
Placebo 8 397 -10.19 (-18.97, -1.42) 0.023 296.38 <0.001 97.6 
Drug 3 258 -23.51 (-37.35, -9.68) 0.001 2.35 0.309 14.9 
Dosage of L-carnitine         
< 2000 mg/d 7 457 -7.52 (-15.54, 0.49) 0.066 261.58 <0.001 97.7 <0.001 
≥ 2000 mg/d 10 634 -14.08 (-22.72, -5.44) 0.001 297.39 <0.001 97 
Duration         
≤ 12 weeks 10 478 -9.59 (-17.54, -1.64) 0.018 523.25 <0.001 98.3 0.099 
> 12 weeks 7 613 -12.77 (-20.63, -4.90) 0.001 80.37 <0.001 92.5 
Overall 17 1091 -10.97 (-16.64, -5.48) <0.001 606.33 <0.001 97.4 - 
AST (IU/L)         
Health status         
Liver disease 8 557 -17.39 (-24.10, -10.67) <0.001 36.57 <0.001 80.9 <0.001 
Without liver disease 10 530 -4.32 (-7.45, -1.18) 0.007 119.94 <0.001 92.5 
Control type         
Without treatment 6 436 -3.91 (-9.19, 1.36) 0.146 79.39 <0.001 93.7 <0.001 
Placebo 10 512 -10.77 (-16.37, -5.18) <0.001 204.09 <0.001 95.6 
Drug 2 139 -29.10 (-43.66, -14.53) <0.001 0.49 0.482 0 
Dosage of L-carnitine         
< 2000 mg/d 7 457 -3.14 (-7.72, 1.43) 0.179 81.27 <0.001 92.6 <0.001 
≥ 2000 mg/d 11 630 -13.53 (-19.43, -7.63) <0.001 204.42 <0.001 95.1 
Duration         
≤ 12 weeks 12 593 -8.62 (-13.06, -4.18) <0.001 253.37 <0.001 95.7 0.604 
>12 weeks 6 494 -10.82 (-19.16, -2.47) 0.011 59.81 <0.001 91.6 
Overall 18 1087 -9.03 (-12.73, -5.33) <0.001 313.44 <0.001 94.6 - 
GGTP (IU/L)         






Figure 1- The detailed steps of the study selection process. 
Figure 2- Forest plots of controlled trials examining the pooled effects of L-carnitine, based 
on the health status of participants (liver disease/without liver disease) on serum levels of 
alanine aminotransferase (ALT) (A), and aspartate aminotransferase (AST) (B). 
Figure 3- Forest plots of controlled trials examining the pooled effects of L-carnitine, as well 
as based on the intervention dose of supplementation (< 2000 mg/d/≥ 2000 mg/d) on serum 
levels of on serum levels of alanine aminotransferase (ALT) (A), and aspartate 
aminotransferase (AST) (B). 
 
